Oral Contrast Agent Market Size, Share and Trends Analysis Report Forecast (2024-2031)
Oral Contrast Agent Market Size, Share and Trends Analysis Report Forecast (2024-2031)
Blog Article
The global oral contrast agent market is anticipated to grow at a significant CAGR 4.8% during the forecast period. Oral contrast agents are barium- or iodine-based. They are used for bowel opacification. Additionally, the concentration of barium determines if it enhances the diagnosis or causes an artifact and obscures pathology. The major factor driving the demand for oral contrast agent is the new product launches and drug approvals across the globe.
Get Sample Copy of this Report at
https://www.omrglobal.com/request-sample/oral-contrast-agent-market
For instance, in December 2021, Bayer announced the approval of two pediatric indications Xarelto (rivaroxaban) from the US Food and Drug Administration (FDA). It is used for the treatment of venous thromboembolism (VTE) and to reduce the risk of recurrent VTE in patients from birth to less than 18 years after at least five days of initial parenteral anticoagulant treatment and thromboprophylaxis in children aged two years and older with congenital heart disease who have undergone the Fontan procedure. Additionally, in December 2021, Ascelia Pharma AB presented a study in which Orviglance was compared against a gadolinium-based contrast agent at RSNA 2021. Orviglance is a novel manganese-based oral contrast agent for magnetic resonance imaging (MRI).
Full Report is Available at
https://www.omrglobal.com/report-customization/oral-contrast-agent-market
Some major players in the market include General Electric Co., Bracco Imaging SpA, and Bayer AG, among others. The market players are contributing significantly to the growth of the market by the adoption of various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay competitive in the market. For instance, in December 2021, Ascelia Pharma AB announced the acceptance of the Investigational New Drug (IND) application for the upcoming global Phase 2 clinical study in gastric cancer with the daily oral chemotherapy candidate drug Oncoral from the US Food and Drug Administration (FDA).
• Competitive Landscape- General Electric Co., Bracco Imaging SpA, and Bayer AG, among others.
By Type
• Barium-based Contrast Media
• Iodinated Contrast Media
• Gadolinium-based Contrast Media
• Microbubble Contrast Media
By Application
• CVD
• Cancer
• Gastrointestinal Disorders
• Musculoskeletal Disorders
• Neurological Disorders
• Nephrological Disorders
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services. The company also offer Digital Marketing services through its subsidiary OMR Digital and Software development and Consulting Services through another subsidiary Encanto Technologies.
Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: [email protected]
Contact no: +91 780-304-0404